Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis

키워드

참고문헌 (84)

1. Bonnans C, "Remodelling the extracellular matrix in development and disease", Nat Rev Mol Cell Biol, 15, pp.786~801 (2014)
2. Iredale JP, "Extracellular matrix degradation in liver fibrosis : biochemistry and regulation", Biochim Biophys Acta, 1832, pp.876~883 (2013)
3. Borthwick LA, "Cytokine mediated tissue fibrosis", Biochim Biophys Acta, 1832, pp.1049~1060 (2013)
4. Liu RM, "Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis", Free Radic Biol Med, 48, pp.1~15 (2010)
5. Rockey DC, "Fibrosis : a common pathway to organ injury and failure", N Engl J Med, 372, pp.1138~1149 (2015)
6. King TE Jr, "Clinical advances in the diagnosis and therapy of the interstitial lung diseases", Am J Respir Crit Care Med, 172, pp.268~279 (2005)
7. Strongman H, "Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK", Adv Ther, 35, pp.724~736 (2018)
8. Hopkins RB, "Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada", Eur Respir J, 48, pp.187~195 (2016)
9. Raghu G, "Idiopathic pulmonary fibrosis : lessons from clinical trials over the past 25 years", Eur Respir J, 50, pp.1701209~ (2017)
10. Noble PW, "Idiopathic pulmonary fibrosis : new insights into pathogenesis", Clin Chest Med, 25, pp.749~758 (2004)
11. Thannickal VJ, "Mechanisms of pulmonary fibrosis", Annu Rev Med, 55, pp.395~417 (2004)
12. Saito A, "TGF-β signaling in lung health and disease", Int J Mol Sci, 19, pp.2460~ (2018)
13. Flanders KC, "Smad3 as a mediator of the fibrotic response", Int J Exp Pathol, 85, pp.47~64 (2004)
14. Nakerakanti S, "The role of TGF-β receptors in fibrosis", Open Rheumatol J, 6, pp.156~162 (2012)
15. Gordon KJ, "Role of transforming growth factor-beta superfamily signaling pathways in human disease", Biochim Biophys Acta, 1782, pp.197~228 (2008)
16. Hoyt DG, "Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice", J Pharmacol Exp Ther, 246, pp.765~771 (1988)
17. Broekelmann TJ, "Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis", Proc Natl Acad Sci U S A, 88, pp.6642~6646 (1991)
18. Wu CF, "Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis", Am J Pathol, 182, pp.118~131 (2013)
19. Border WA, "Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease", Nature, 360, pp.361~364 (1992)
20. Isaka Y, "Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction", Kidney Int, 58, pp.1885~1892 (2000)
21. Takabatake Y, "Exploring RNA interference as a therapeutic strategy for renal disease", Gene Ther, 12, pp.965~973 (2005)
22. Zhao J, "Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice", Am J Physiol Lung Cell Mol Physiol, 282, pp.L585~L593 (2002)
23. Zi Z, "Dynamics of TGF-β", Smad signaling, 2012, pp.586, 1921~1928
24. Zhang YE, "Non-Smad pathways in TGF-beta signaling", Cell Res, 19, pp.128~139 (2009)
25. Bringardner BD, "The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis", Antioxid Redox Signal, 10, pp.287~301 (2008)
26. Selman M, "Idiopathic pulmonary fibrosis : an epithelial", fibroblastic cross-talk disorder, 2002, pp.3, 3~
27. Sakai N, "Fibrosis of two : epithelial cell-fibroblast interactions in pulmonary fibrosis", Biochim Biophys Acta, 1832, pp.911~921 (2013)
28. Camelo A, "The epithelium in idiopathic pulmonary fibrosis : breaking the barrier", Front Pharmacol, 4, pp.173~ (2014)
29. Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)
30. Ogura T, "Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis", Eur Respir J, 45, pp.1382~1392 (2015)
31. Taniguchi H, "Pirfenidone in idiopathic pulmonary fibrosis", Eur Respir J, 35, pp.821~829 (2010)
32. Gurujeyalakshmi G, "Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level", Am J Physiol, 276, pp.L311~L318 (1999)
33. Iyer SN, "Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis", J Pharmacol Exp Ther, 291, pp.367~373 (1999)
34. Noble PW, "Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY) : two randomised trials", Lancet, 377, pp.1760~1769 (2011)
35. Lopez-de la Mora DA, "Role and new insights of pirfenidone in fibrotic diseases", Int J Med Sci, 12, pp.840~847 (2015)
36. King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
37. Jiang C, "Adverse events of pirfenidone for the treatment of pulmonary fibrosis : a meta-analysis of randomized controlled trials", PLoS One, 7, pp.e47024~ (2012)
38. Wollin L, "Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis", Eur Respir J, 45, pp.1434~1445 (2015)
39. Hostettler KE, "Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis", Respir Res, 15, pp.157~ (2014)
40. Wollin L, "Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis", J Pharmacol Exp Ther, 349, pp.209~220 (2014)
41. Richeldi L, "Design of the INPULSIS™ trials : two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis", Respir Med, 108, pp.1023~1030 (2014)
42. Meng XM, "TGF-β : the master regulator of fibrosis", Nat Rev Nephrol, 12, pp.325~338 (2016)
43. Choi ME, "Mechanism of transforming growth factor-β1 signaling : role of the mitogen-activated protein kinase", Kidney Int, 58(Suppl 77), pp.S53~S58 (2000)
44. Leask A, "All in the CCN family : essential matricellular signaling modulators emerge from the bunker", J Cell Sci, 119(Pt 23), pp.4803~4810 (2006)
45. Yue X, "TGF-β : titan of lung fibrogenesis", Curr Enzym Inhib, 6 (2010)[DOI]
46. Varga J, "Systemic sclerosis : a prototypic multisystem fibrotic disorder", J Clin Invest, 117, pp.557~567 (2007)
47. Derynck R, "Smad-dependent and Smad-independent pathways in TGF-beta family signalling", Nature, 425, pp.577~584 (2003)
48. Das F, "Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1", J Cell Physiol, 214, pp.513~527 (2008)
49. Munger JS, "The integrin αvβ6 binds and activates latent TGFβ1 : a mechanism for regulating pulmonary inflammation and fibrosis", Cell, 96, pp.319~328 (1999)
50. Mackinnon AC, "Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3", Am J Respir Crit Care Med, 185, pp.537~546 (2012)
51. Brigstock DR, "The connective tissue growth factor", cysteine-rich 61, Endocr Rev, pp.1999, 20[DOI]
52. Kondo S, "Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases", Carcinogenesis, 23, pp.769~776 (2002)
53. Shimo T, "Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis", Oncology, 61, pp.315~322 (2001)
54. Takigawa M, "CTGF", Hcs24 as a multifunctional growth factor for fibroblasts, chondrocytes and vascular endothelial cells, 2003, pp.16, 11~21
55. Igarashi A, "Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair", Mol Biol Cell, 4, pp.637~645 (1993)
56. Grotendorst GR, "A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene", Cell Growth Differ, 7, pp.469~480 (1996)
57. Shimo T, "Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line", Cancer Lett, 174, pp.57~64 (2001)
58. Suzuma K, "Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells", J Biol Chem, 275, pp.40725~40731 (2000)
59. Lau LF, "Cell surface receptors for CCN proteins", J Cell Commun Signal, 10, pp.121~127 (2016)
60. Wang Q, "Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease", Fibrogenesis Tissue Repair, 4, pp.4~ (2011)
61. Kono M, "Plasma CCN2(connective tissue growth factor; CTGF)is a potential biomarker in idiopathic pulmonary fibrosis(IPF)", Clin Chim Acta, 412, pp.2211~2215 (2011)
62. Pan LH, "Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF", Eur Respir J, 17, pp.1220~1227 (2001)
63. Gabbiani G, "Modulation of fibroblastic cytoskeletal features during wound healing and fibrosis", Pathol Res Pract, 190, pp.851~853 (1994)
64. Sandbo N, "Actin cytoskeleton in myofibroblast differentiation : ultrastructure defining form and driving function", Transl Res, 158, pp.181~196 (2011)
65. Knipe RS, "The Rho kinases : critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis", Pharmacol Rev, 67, pp.103~117 (2015)
66. Zhou Y, "Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis", J Clin Invest, 123, pp.1096~1108 (2013)
67. Griffith DE, "Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open- label, randomized study", Am J Respir Crit Care Med, 198, pp.1559~1569 (2018)
68. Yoshida K, "MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis", J Pathol, 198, pp.388~396 (2002)
69. Alcorn JF, "c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis", Am J Respir Cell Mol Biol, 40, pp.422~432 (2009)
70. Van der Velden JL, "Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models", PLoS One, 15, pp.e0226904~ (2020)
71. Bennett B, "CC-90001, a second generation Jun N-terminal kinase(JNK)inhibitor for the treatment of idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 195, pp.A5409~ (2017)
72. Van der Velden JL, "JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers", Clin Transl Med, 5, pp.36~ (2016)
73. Clement DL, "PDGFRα signaling in the primary cilium regulates NHE1-dependent fibroblast migration via coordinated differential activity of MEK1", 2-ERK1, J Cell Sci, pp.2013, 126(Pt 4)[DOI]
74. Delehedde M, "Fibroblast growth factor-2 stimulation of p42", 44MAPK phosphorylation and IkappaB degradation is regulated by heparan sulfate, J Biol Chem, pp.2000, 275[DOI]
75. Seko Y, "Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes", J Cell Physiol, 175, pp.239~246 (1998)
76. Rovida E, "ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells", J Hepatol, 48, pp.107~115 (2008)
77. Roberts OL, "ERK5 and the regulation of endothelial cell function", Biochem Soc Trans, 37(Pt 6), pp.1254~1259 (2009)
78. Kimura TE, "Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart", Circ Res, 106, pp.961~970 (2010)
79. Urushihara M, "ERK5 activation enhances mesangial cell viability and collagen matrix accumulation in rat progressive glomerulonephritis", Am J Physiol Renal Physiol, 298, pp.F167~F176 (2010)
80. Kim S, "ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation", Am J Pathol, 183, pp.1758~1768 (2013)
81. Frodin M, "Role and regulation of 90 kDa ribosomal S6 kinase(RSK)in signal transduction", Mol Cell Endocrinol, 151, pp.65~77 (1999)
82. Morales-Ibanez O, "Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis", Gut, 65, pp.840~851 (2016)
83. Jo E, "Kaempferol suppresses transforming growth factor-β1-induced epithelial-to-mesenchymal transition and migration of A549 lung cancer cells by inhibiting akt1-mediated phosphorylation of Smad3 at threonine-179", Neoplasia, 17, pp.525~537 (2015)
84. Kim S, "p90RSK inhibition ameliorates TGF-β1 signaling and pulmonary fibrosis by inhibiting Smad3 transcriptional activity", Cell Physiol Biochem, 54, pp.195~210 (2020)

관련 논문AI추천